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Abstract
Objectives Previous studies suggest that maximum tumor
diameter (MTD) is a predictor of recurrence in prostate
cancer (PC). This study investigates the prognostic value of
MTD for biochemical recurrence (BCR) in patients with
PC, after radical prostatectomy (RP), with emphasis on
high-risk localized prostate cancer.
Methods RP specimens of 542 patients were evaluated
with a median follow-up of 39.5 months (range 0.6–
150 months). MTD was deWned as the largest diameter of
the largest tumor; high-risk as ¸T2c or PSA level > 20 ng/
ml or Gleason score ¸8 and BCR as two consecutive PSA
levels > 0.10 ng/ml. Proportional hazards multivariable
regression models were composed to determine prognostic
factors for BCR.
Results Overall, 114 patients developed BCR after RP. The
overall 5-year risk of BCR was 25% (95% CI = 20.4–29.6),
and median MTD was 24 mm (range 1–65). MTD in the
total and high-risk group was associated with total tumor
volume, volume of the largest tumor, pre-operative PSA
levels, and Gleason score. In a univariable analyses, MTD
was weakly associated with risk of BCR (HR = 1.02 per
mm increase, 95% CI = 1.002–1.035, P = 0.024) in the
total group; in the high-risk group this association was lost
(HR = 1.01, 95%CI = 0.99–1.03, P = 0.18). Multivariable
analyses indicated that positive surgical margins, higher
Gleason score, advanced pathological stage, and multiple
tumors were the main prognostic factors for BCR irrespec-
tive of the risk proWle. MTD did not provide additional
information.
Conclusions MTD is not an independent prognostic factor
for BCR in patients treated with RP, irrespective of the risk
proWle.
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Introduction
The characteristics mostly used to predict progression of
prostate cancer (PC), after radical prostatectomy (RP), are
Gleason score, pre-operative PSA level, pathological stag-
ing, positive surgical margins, and tumor volume (TV). [1]
The Wrst three are also used to deWne high-risk localized PC
[2]. TV in the RP specimen is also clearly associated with
prognosis. However, whether it is an independent prognos-
tic factor, both for the total group and for the high-risk
group, still remains controversial [3].
Epstein et al. [4] stated that, although TV is a predictor
of progression, it did not provide additional information
over Gleason score and pathological stage. This was also
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score and pathological stage were independent factors to
predict progression after RP. If these parameters were
known, TV did not provide any additional information.
This is in contrast with Stamey et al. [6] who found that TV
is an independent prognostic parameter for PC progression.
These Wndings were also observed in other studies [7–9].
None of these studies, however, speciWcally addressed the
high-risk subgroup. An explanation of these conXicting
results might be that TV estimations can be done with the
help of several techniques, as Humphrey and Volmer [10]
described earlier. Moreover, these techniques are rather
complex and time-consuming. Therefore, maximum tumor
diameter (MTD) has been suggested as a fast and easy
proxy for TV. Renshaw et al. [11] noted that simple mea-
surements of the largest diameter of the largest tumor from
glass slides is a predictor of PSA failure. This was sup-
ported by Eichelberger et al. [12] who showed that MTD
correlates with TV and other potential prognostic factors
for clinical outcome. However, these studies had either a
small number of patients with a relatively short follow-up
(57 patients, median follow-up 27.2 months) or did not
investigate the correlation between MTD and biochemical
recurrence (BCR).
Therefore, in this present study, with a large cohort of
542 RP specimens, and a median follow-up of 39.5 months,
we studied the prognostic value of MTD, as a surrogate for
tumor volume, for BCR in patients with PC, with special
attention to the high-risk group.
Materials and methods
Between 1992 and 2005, 617 patients were treated with RP
for clinically localized PC at our institute. Of these patients,
75 were excluded from analyses because of HIFU treat-
ment, hormonal pre-treatment or irradiation before RP. Of
the remaining 542 patients, Wve had incomplete follow-up
data. Charts were examined retrospectively for clinical fol-
low-up data and risk group classiWcation. These risk groups
were classiWed according to D’Amico et al. [2]. High risk
was deWned as stage ¸T2c or PSA level >20 ng/ml or Glea-
son score ¸8, and we formed one group of the low and
intermediate risk group (stage < T2c, PSA level · 20 ng/ml
and Gleason score · 7).
All RP specimens were Wxed overnight, inked, and cut
into serial, transverse, 4 mm thick slices according to a
standard protocol by Ruijter et al. [13]. In brief, the apical
and basal margins were amputated to a thickness of 4 mm
and sectioned parasagittally at 4 mm intervals. The seminal
vesicles were sectioned parallel and entirely submitted. The
prostate was then sectioned perpendicularly to the long axis
(apical to basal) of the gland along the posterior rectal
surface at 4-mm intervals. Tumor was outlined on the
microscopic glass slides and schematically drawn on the
macroscopically photographed transverse sections in order
to be able to reconstruct tumor extension and tumor multi-
focallity. Detailed pathological analysis, including number
of tumors, total volume of all tumors, MTD, pathological
staging, Gleason score, extracapsular extension and posi-
tive margins, was performed by a single pathologist (CAHK).
Tumors were staged using the American Joint Committee
on Cancer (AJCC) TNM staging criteria of 2002 [14].
MTD was deWned as the largest diameter of the largest
tumor. MTD was determined by marking both ends of the
tumor and measuring the distance at the glass slide directly.
If the tumor was present on consecutive glass slides, thick-
ness of the slices of the concerning sections was summed.
This reconstructed diameter was considered as MTD if it
was larger than the diameter, and was visualized directly on
the glass slides.
PSA values were obtained before surgery and at every
follow-up point. BCR after RP was deWned as two subse-
quent PSA levels above 0.10 ng/ml among patients who
reached non-measurable levels after RP.
Statistical analysis
Baseline characteristics are summarized with median and
interquartile ranges (IQR). Associations between MTD and
clinical or pathological characteristics were examined by
univariate regression models. Kaplan–Meier curves were
used to assess the risk of BCR. Proportional hazards multi-
variable regression models were composed to determine
prognostic factors for BCR. SPSS version 12.0.1 for
Windows was used for all statistical analysis.
Results
Patient and tumor characteristics are summarized in
Table 1. The age of the patients at time of RP was
62.7 years (IQR 58.4–66.5 years) and they had a median
Gleason score of 6. In the specimens, a median MTD of
24.0 mm (IQR 16.0–32.0 mm) was found. Patients were
followed for a median period of 39.5 months (IQR 17.1–
67.3 months). Overall, 114 (21%) patients developed BCR
after RP. The median time to PSA recurrence was
20.3 months (IQR 10.3–46.9). The overall 5-year Kaplan–
Meier risk of BCR was 25% (95% CI = 20.4–29.6) for the
whole group. For the high-risk group and low/intermediate
risk, these were 27.4 (95% CI = 22.2–32.6) and 10% (95%
CI = 2.2–17.8), respectively. Totally, 432 of the 542
patients fulWlled the criteria for high-risk localized PC, 72
patients were low/intermediate risk, and 38 patients never
reached non-measurable PSA levels.123
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istics are summarized in Table 2. Overall we found 359
organ-conWned (T2) tumors, 116 extracapsular extended
tumors (T3a), and 52 tumors invaded into seminal vesicles
(T3b). Half of all the patients (n = 271) had positive surgical
margins and eight patients had lymph node involvement.
Pre-operative PSA levels ranged from 0.1–87.2 ng/ml
(median 8.0 ng/ml). Kruskall–Wallis tests or Mann–Whitney
U test revealed that MTD was signiWcantly associated with
pathological stage (P < 0.001), Gleason score (P < 0.001),
margin status (P < 0.001), number of tumors (P < 0.001)
and pre-operative PSA levels (P < 0.001). Positive surgical
margins were associated with a larger MTD compared to
negative surgical margins. Single tumors were also found
to have a larger MTD than multiple tumors. Extracapsular
extension (T3a) and invasion to seminal vesicles (T3b)
were both associated with larger maximal tumor diameters
compared to those of organ-conWned (T2) tumors. MTD in
the high-risk group was signiWcantly higher then in the low/
intermediate risk group (median 24.5 vs.14.0 mm,
P < 0.001). We also calculated the correlation coeYcient
for MTD and all other factors. We found that MTD was
signiWcantly correlated to index TV (=largest tumor)
(r = 0.60, P < 0.001) and total TV (r = 0.61, P < 0.001) in
the total group. In the high-risk group, these correlations
were weaker. In addition, signiWcant correlations with
MTD were found for Gleason score (r = 0.17, P < 0.001),
the number of tumors (r = ¡0.21, P < 0.001) and pre-oper-
ative PSA levels (r = 0.38, P < 0.001).
Univariable analyses of MTD as a continuous variable
revealed that it is weakly associated with risk of BCR
(HR = 1.02 per mm increase, 95% CI = 1.00–1.04,
P = 0.024). In the high-risk group, this association was lost
(HR = 1.01 per mm increase, 95%CI = 0.99–1.03,
P = 0.18).
In the total group TV, pre-operative PSA levels, patho-
logical stage, and Gleason score were associated with risk
of BCR, as presented in Table 3. Proportional hazards mul-
tivariable regression models were composed to determine
signiWcant independent prognostic factors (Table 3). Posi-
tive surgical margins, higher Gleason score, advanced path-
ological stage, and multiple tumors were the main
prognostic factors for BCR. Neither MTD nor tumor
volume turned out to be signiWcant in either group.
Discussion
Prediction of outcome after RP in patients with localized
PC is important to tailor follow up, and for example, to con-
sider adjuvant therapy in patients at high risk for recur-
rence. Several studies have assessed the value of
morphological and clinical variables in this respect. Tumor
stage, Gleason score, and pre-operative PSA levels are
obvious parameters, and also used to deWne patients at
high-risk for recurrence [2]. MTD, as easy to determine
surrogate for tumor volume [12], is another potential vari-
able considered as a potential predictor of BCR. In our
study of 542 patients, we found that MTD correlates with
index TV, total TV, pathological stage, Gleason score, num-
ber of tumors, and pre-operative PSA levels irrespective of
Table 1 Patient and pathological characteristics (n = 542)
Data are presented as median and interquartile ranges (IQR)
Median IQR
Age (years) 62.7 58.4–66.5
Follow-up period (months) 39.5 17.1–67.3
Pre-operative PSA (ng/ml) 8.0 5.5–13.0
Gleason score 6 5–7
Number of tumors (n) 2 1–3
Index tumor volume (cm3) 1.6 0.6–3.4
Total tumor volume (cm3) 2.0 0.8–3.9
Maximal tumor diameter (mm) 24.0 16.0–32.0
Table 2 Associations between MTD and pathological characteristics
* P-values were assessed by aKruskal–Wallis test or bMann–Whitney
U test
No. of 
patients
Maximum tumor diameter
Mean Median Range P-value*
Pathological stagea (2002)
T2 359 21.0 20.0 1–60 <0.001
T3a 116 30.8 28.0 12–60
T3b 52 31.1 31.0 3–55
Gleason scorea
·6 301 22.5 21.0 1–65 <0.001
3 + 4 136 26.2 25.0 8–60
4 + 3 22 25.0 24.0 3–49
¸8 80 28.8 28.0 4–60
Margin statusb
Negative 270 20.5 20.0 1–52 <0.001
Positive 271 28.5 28.0 3–65
Number of tumorsb
1 241 27.3 26.0 1–65 <0.001
¸1 301 22.3 22.0 1–50
Pre-operative PSAa
<4 56 17.4 15.0 3–46 <0.001
4–10 289 23.6 24.0 1–55
10–20 123 24.5 24.0 2–55
>20 70 34.4 35.5 10–65
Risk groupsb
High 432 25.8 24.5 1–65 <0.001
Low/intermediate 72 14.3 14.0 1–36123
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predictor of BCR in the total or in the high-risk subgroup.
For the whole group, these results are in contrast with
previously reported Wndings.
One of the Wrst studies addressing the association of
MTD and BCR was by Renshaw et al. [3]. In this study,
with 57 patients undergoing RP, it was found that MTD
was strongly correlated with total TV. In this small series, a
high MTD was associated with a slight increased risk for
BCR (HR 1.12) that was marginally signiWcant. Their sub-
sequent study was a larger cohort of 434 patients. The
median MTD was 13 mm. The median follow-up was
12.9 months and 27.2% of patients had PSA failure. This
study conWrmed that MTD is an independent predictor of
BCR, even after adjustment for other risk factors [11].
Their next study by Dvorak et al. [15] had an even larger
cohort (781 patients) and longer median follow-up
(64.8 months). MTD remained the same with a median of
13 mm, and BCR in 31% of the patients. Again they found
that MTD was signiWcantly associated with time to BCR
(HR = 1.04, P = 0.004) adjusted for pre-op PSA, Gleason
score, and pathological stage. But when surgical margin
status was added, MTD lost statistical signiWcance
(P = 0.07). One important feature of these studies is that the
RP specimens were not uniformly processed. Therefore, we
have to be taking into account the variation in evaluation of
the prognostic factors. Another diVerence with our results is
that the median MTD in these three studies (13 mm) are
less than in our study (24 mm). This might be explained by
the way we determine our MTD. Renshaw et al. limited
their measurements to the single focus of tumor that could
be demonstrated on one slide (slice-MTD). We, on the
other hand, take the largest diameter of the largest tumor
after reconstruction (real-MTD). To see if we could explain
this diVerence, we also measured the slice-MTD in a part of
our cohort. In 250 consecutive cases from 2000 to 2005, we
found a median slice-MTD of 19 mm and a median real-
MTD of 24 mm. This strongly suggests that part of the
diVerence in MTD is caused by the diVerent way MTD is
measured. The diVerence that still exists could be explained
by the fact that Renshaw et al. used partially submitted
prostates, thus missing part of the prostates for evaluation.
The only study where they did use uniformly processed
specimens is by Eichelberger et al., but this study has a
very short follow-up. They analyzed the prognostic value of
MTD in a cohort of 364 patients treated with RP, and found
a mean MTD of 17.3 mm and biochemical recurrence in
12% of the patients [16]. In this study with a median
follow-up of only 12 months, they found that MTD was a
signiWcant predictor of BCR, adjusted for Gleason score
and surgical margin status (HR = 1.70, P = 0.011). In our
study we found a median time to BCR of 20.3 months,
hence a follow-up of 12 months seems not long enough to
investigate BCR.
Another striking diVerence is the percentage of positive
surgical margins. In our study this is relatively high (50%)
compared to other studies (Renshaw et al. 31 and 26%,
Eichelberger et al. 23%, Dvorak et al. 27%). Our median
BCR rate (21% after 39.5 months), however, was compara-
ble to the median of these studies [Renshaw 27%
Table 3 Univariable and multi-
variable analysis of clinical and 
pathological characteristics 
associated with time to BCR
Covariates Univariable Multivariable
HR 95% CI AHR 95% CI
Pre-operative PSA 1.02 1.01–1.04*
Pathological stage
pT2 1.0 1.0
pT3a 2.12 1.39–3.23* 1.26 0.81–1.97#
pT3b 3.90 2.33–6.53* 1.79 1.02–3.13*
Gleason score
·6 1.0 1.0
3 + 4 2.64 1.64–4.25* 1.97 1.20–3.23*
4 + 3 7.27 3.18–16.63* 5.71 2.47–13.20*
¸8 5.68 3.60–8.97* 3.57 2.17–5.89*
Extracapsular extension 2.71 1.87–3.94*
Invasion seminal vesicle 3.07 1.94–4.87*
Margin status 4.64 3.02–7.12* 3.75 2.36–5.96*
Number of tumors 1.02 0.88–1.17# 1.18 1.02–1.36*
Maximal tumor diameter 1.02 0.99–1.04#
Index tumor volume 1.04 1.02–1.07*
Total tumor volume 1.04 1.02–1.07*
HR hazard ratio, CI conWdence 
interval, AHR adjusted hazard 
ratio
* P < 0.05, # P > 0.05123
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31% (64.8 months)]. An explanation for the high number of
positive surgical margins, next to surgical techniques, is
that by evaluating only partially included prostates you
miss positive surgical margins.
The diVerence between our study and studies like
Eichelberger et al, in which the entire prostate was histo-
logically examined using whole mount sections, are less
easily explained, but here the interval at which the prostates
were sliced is higher (mean 7.8 mm according to the used
protocol described by Qian et al. [17], personal communi-
cation). From this, we can conclude that MTD is not an
independent prognostic marker if surgical resection
margins are accurately documented.
Finally, none of the mentioned studies separately looked
at the group where prediction might be of most importance,
the high-risk group. As clearly indicated, in this group,
neither MTD nor TV is of any signiWcant value.
In all, we do not advice to use MTD as a prognostic fac-
tor for BCR, since after proper follow-up and with adequate
pathological techniques it does not add anything to other
readily available prognostic factors. Moreover, in the high-
risk group, TV is not an independent prognostic factor at all.
Conclusions
The results of our study suggest that MTD is positively cor-
related to total TV, as can be expected. MTD was weakly
associated with risk of BCR and this association was lost in
the high-risk group. If adjusted for positive surgical mar-
gins, higher Gleason score, advanced pathological stage,
and multiple tumors, MTD did not provide additional
information.
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